Wall Street analysts expect Merus N.V. (NASDAQ:MRUS) to announce $2.59 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Merus N.V.’s earnings. The lowest sales estimate is $1.94 million and the highest is $3.23 million. Merus N.V. reported sales of $1.24 million in the same quarter last year, which indicates a positive year-over-year growth rate of 108.9%. The business is expected to announce its next earnings report on Monday, August 14th.
On average, analysts expect that Merus N.V. will report full year sales of $2.59 million for the current financial year, with estimates ranging from $8.58 million to $11.04 million. For the next fiscal year, analysts expect that the company will report sales of $17.13 million per share, with estimates ranging from $7.89 million to $26.37 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Merus N.V..
Several equities research analysts recently weighed in on MRUS shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $33.00 price target on shares of Merus N.V. in a report on Wednesday, April 26th. Zacks Investment Research downgraded Merus N.V. from a “hold” rating to a “sell” rating in a report on Friday, May 5th. ValuEngine upgraded Merus N.V. from a “sell” rating to a “hold” rating in a research report on Saturday, May 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $32.00 price objective on shares of Merus N.V. in a research report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Merus N.V. has an average rating of “Hold” and a consensus price target of $26.00.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Spark Investment Management LLC purchased a new position in shares of Merus N.V. during the first quarter worth $458,000. Renaissance Technologies LLC purchased a new position in shares of Merus N.V. during the first quarter worth $549,000. Norges Bank purchased a new position in shares of Merus N.V. during the fourth quarter worth $790,000. Victory Capital Management Inc. purchased a new position in shares of Merus N.V. during the first quarter worth $976,000. Finally, Iguana Healthcare Management LLC boosted its position in shares of Merus N.V. by 16.7% in the first quarter. Iguana Healthcare Management LLC now owns 175,000 shares of the biotechnology company’s stock worth $4,268,000 after buying an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 32.59% of the company’s stock.
Merus N.V. Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Merus N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merus N.V. and related companies.